Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

International recognition for Mainz-based research on altermagnetism, a new concept in physics.

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

A significant breakthrough in treating the Human Immunodeficiency Virus came recently with the US Federal Drug Administration approving lenacapavir, a new prototype medication. It uses a unique ...

Every year, the high-profile academic journal "Science" names ten groundbreaking discoveries in a top list of scientific breakthroughs. For 2024, "Science" chose the drug lenacapavir and its potential ...